Curio Wealth’s United Therapeutics UTHR Stock Holding History

Curio Wealth’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1	Closed	-$593	–	1090
2026 Q1	$593	Buy	+1	New	+$498	﹤0.01%	473

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Norges Bank Oslo, Norway $1T AUM

Curio Wealth's UTHR Position: Q2 2026 in Review

Curio Wealth sold out of United Therapeutics (UTHR) in Q2 2026, closing a stake of 1 share — an estimated $593 sold.

Curio Wealth first reported a position in UTHR in Q1 2026 and held it in 1 quarter. The position peaked at $593 in Q1 2026. 878 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

Curio Wealth reported no remaining United Therapeutics position as of Q2 2026 after selling out during the quarter.
Curio Wealth sold 1 United Therapeutics share in Q2 2026, an estimated $593.
Curio Wealth first reported a position in United Therapeutics in Q1 2026 and held it in 1 quarter.
Curio Wealth's United Therapeutics position peaked at $593 in Q1 2026.
878 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Curio Wealth's 13F filing for Q2 2026, filed 7 Aug 2026.